Last reviewed 2026-04-22 · How we verify

CCRT+ PF

CCRT+ PF is a combination regimen pairing concurrent chemoradiotherapy with a fluoropyrimidine-based chemotherapy backbone.

CCRT+ PF is a combination regimen pairing concurrent chemoradiotherapy with a fluoropyrimidine-based chemotherapy backbone. Used for Locally advanced solid tumors (specific indication not clearly defined in available data).

At a glance

Mechanism of action

This is a treatment protocol combining concurrent chemoradiotherapy (CCRT) with fluoropyrimidine chemotherapy (likely 5-FU or capecitabine). The concurrent approach aims to enhance local tumor control through radiation while systemic chemotherapy addresses micrometastatic disease. The fluoropyrimidine component acts as a radiosensitizer and provides cytotoxic activity.

Approved indications

• Locally advanced solid tumors (specific indication not clearly defined in available data)

Common side effects

• Mucositis
• Hematologic toxicity
• Gastrointestinal toxicity
• Radiation dermatitis

Key clinical trials

• GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma (PHASE3)
• Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma (PHASE3)
• TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma (PHASE3)
• TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma (PHASE3)
• Eating Difficulties in HNC Patients - Influencing Factors and Short and Long Term Impacts on PF and Depression
• Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC (PHASE2)
• TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.